4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass
2015 · Blood · 11 citations
https://doi.org/10.1182/blood.v126.23.264.264
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
47
Papers
979
Citations
13
h-index
16
i10-index
Lujia Dong is an academic researcher from Xidian University. The author has contributed to research in topics: Hematopoietic Stem Cell Transplantation & CAR-T cell therapy research & Cytomegalovirus and herpesvirus research. The author has an h-index of 13, co-authored 40 publications.
https://doi.org/10.1182/blood.v126.23.264.264
https://doi.org/10.1016/j.heliyon.2024.e37346
Click to start Chat